蓝丰生化：第七届董事会第三十次会议决议公告

Group 1 - The core point of the article is that Lanfeng Biochemical announced the approval of a proposal regarding the capital increase and expansion of its controlling subsidiary, while the company will waive its preemptive subscription rights [2] Group 2 - The announcement was made during the 30th meeting of the 7th Board of Directors [2]